Table 2.
Un-weighted and IPT-weighted Kaplan-Meier and competing risk of any urinary adverse event
| Control | EBRT | BT | BT + EBRT | RP | RP + EBRT | Cryotherapy | |
|---|---|---|---|---|---|---|---|
| Subjects (n) | 144,816 | 44,318 | 14,259 | 11,835 | 26,790 | 1557 | 2115 |
| Un-weighted KMa | |||||||
| Event rate (n per 100 person-yr) | 1.78 | 2.40 | 2.70 | 3.91 | 4.02 | 6.08 | 3.71 |
| KM 10-yr. cumulative incidence (%) | 16.1 | 19.7 | 19.8 | 28.4 | 26.6 | 37.8 | 23.4 |
| IPT-weighted KMa | |||||||
| KM 10-yr. cumulative incidence (%) | 17.0 | 17.6 | 20.0 | 27.4 | 27.2 | 36.4 | 19.4 |
| HRb | 1 | 1.114 | 1.428 | 1.969 | 2.442 | 3.194 | 1.56 |
| 95% CI | 1.07, 1.16 | 1.33, 1.53 | 1.85, 2.10 | 2.34, 2.55 | 2.79, 3.66 | 1.30, 1.87 | |
| Un-weighted CR | |||||||
| KM 10-yr. cumulative incidence (%) | 12.1 | 16.4 | 18.1 | 25.8 | 25.6 | 36.2 | 22.4 |
| HRc | 1 | 1.430 | 1.660 | 2.416 | 2.835 | 4.057 | 2.082 |
| 95% CI | 1.38, 1.48 | 1.58, 1.74 | 2.31, 2.53 | 2.75, 2.93 | 3.70, 4.46 | 1.85, 2.35 | |
| IPT-weighted CR | |||||||
| KM 10-yr. cumulative incidence (%) | 12.7 | 14.8 | 18.3 | 25.2 | 26.0 | 36.5 | 22.1 |
| HRd | 1 | 1.194 | 1.585 | 2.214 | 2.761 | 3.655 | 1.754 |
| 95% CI | 1.15, 1.24 | 1.50, 1.67 | 2.11, 2.32 | 2.67, 2.86 | 3.28, 4.07 | 1.54, 1.99 |
Abbreviations: EBRT external beam radiotherapy, BT brachytherapy, RP radical prostatectomy, UAE urinary adverse event, KM Kaplan-Meier, CR competing risks, HR hazard ratio, CI confidence interval
aResults from the Jarosek et al. paper for un-weighted KM and IPT-weighted KM models
bCox proportional hazard model with inverse probability weighting
cCompeting risks analysis model
dCompeting risks analysis model with inverse probability of treatment weighting